Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

Stephen M. Ansell

doi:10.1016/S2352-3026(18)30210-2

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

Stephen M. Ansell

Hematology

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	e2-e3
Journal	The Lancet Haematology
Volume	6
Issue number	1
DOIs	https://doi.org/10.1016/S2352-3026(18)30210-2
State	Published - Jan 2019

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/S2352-3026(18)30210-2

Cite this

@article{14a02464ba5c4d389eadbce99fd1f5f6,

title = "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma",

author = "Ansell, {Stephen M.}",

year = "2019",

month = jan,

doi = "10.1016/S2352-3026(18)30210-2",

language = "English (US)",

volume = "6",

pages = "e2--e3",

journal = "The Lancet Haematology",

issn = "2352-3026",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Sintilimab

T2 - another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

AU - Ansell, Stephen M.

PY - 2019/1

Y1 - 2019/1

UR - http://www.scopus.com/inward/record.url?scp=85059346064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059346064&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(18)30210-2

DO - 10.1016/S2352-3026(18)30210-2

M3 - Comment/debate

C2 - 30612711

AN - SCOPUS:85059346064

SN - 2352-3026

VL - 6

SP - e2-e3

JO - The Lancet Haematology

JF - The Lancet Haematology

IS - 1

ER -

Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this